Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 29.54 |
|---|---|
| High | 29.54 |
| Low | 29.54 |
| Bid | 29.53 |
| Offer | 29.69 |
| Previous close | 33.52 |
| Average volume | 136.67 |
|---|---|
| Shares outstanding | 105.19m |
| Free float | 93.07m |
| P/E (TTM) | 38.65 |
| Market cap | 3.60bn USD |
| EPS (TTM) | 0.8858 USD |
Data delayed at least 15 minutes, as of Feb 20 2026 07:00 GMT.
More ▼
Press releases
- Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
- Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
- Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
